1ac3f1b2-5b83-470c-b1d3-d35d813f3e65
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.430
- MYC_TARGETS_V1+0.370
- G2M_CHECKPOINT+0.310
- OXIDATIVE_PHOSPHORYLATION+0.300
- SPERMATOGENESIS+0.250
- PROTEIN_SECRETION+0.230
- FATTY_ACID_METABOLISM+0.220
- PEROXISOME+0.190
- DNA_REPAIR+0.170
- MYC_TARGETS_V2+0.170
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- ALLOGRAFT_REJECTION-0.490
- INTERFERON_GAMMA_RESPONSE-0.490
- ANGIOGENESIS-0.470
- INTERFERON_ALPHA_RESPONSE-0.470
- IL6_JAK_STAT3_SIGNALING-0.440
- MYOGENESIS-0.430
- HEDGEHOG_SIGNALING-0.400
- NOTCH_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-A4IG-01A-11R-A266-07 | — | — | 0.891 |
| 2 | TCGA-BB-8601-01A-11R-2403-07 | — | — | 0.874 |
| 3 | R321 | — | — | 0.870 |
| 4 | 20040104.LumB | — | B | 0.870 |
| 5 | R6 | — | — | 0.867 |
| 6 | MDT-AP-3402 | Med | Medulloblastoma | 0.865 |
| 7 | MNG489 | — | — | 0.862 |
| 8 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.857 |
| 9 | TCGA-C8-A1HN-01A-11R-A137-07 | — | B | 0.855 |
| 10 | TCGA-QK-A8ZA-01A-11R-A39I-07 | — | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |